UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

IDEXX Q1 2024 Earnings Highlights (NASDAQ: IDXX) IDEXX Q1 2025 Earnings Highlights (NASDAQ: IDXX) | Revenue | | | Operating | | | Diluted | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Profit | | | Earnings Per Share | | | | | $998M | | | $317M | | | $2.96 | | | | | Reported growth: | +4% | 31.7% | of Revenue | | | | | | | | | | | | | | Reported growth: | | +5% | | | Organic growth: | +5% | YoY change in basis points: | | | | | | | | | CAG Diagnostics Recurring | | Reported | ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.37%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.40 per share when it actually produced earnings of $2.62, delivering a surprise of 9.17%.Over t ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the IDEXX Laboratories First Quarter twenty twenty five Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelski, President and Chief Executive Officer Andrew Emerson, Chief Financial Officer and John Rebus, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forwa ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO and TreasurerJay Mazelsky - President and CEOMichael Ryskin - Managing DirectorKatarina Markovic - Executive DirectorJonathan Block - Managing DirectorDaniel Clark - VP - Equity Research Conference Call Participants Erin Wright - AnalystBrandon Vazquez - Research AnalystDavid Westenberg - Managing Director & Senior Research AnalystNavann Ty Dietschi - Lead Analyst Operator Good mo ...

Exhibit 99.1 First Quarter Results FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 1, 2025— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. "IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, ID ...

Idexx Laboratories (IDXX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 1, 2025, might help the stock move higher if these key numbers are better than ...

IDEXX Laboratories, Inc. (IDXX) is set to release first-quarter 2025 results on May 1, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.62, which surpassed the Zacks Consensus Estimate by 9.2%. IDEXX Laboratories’ earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 0.78%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).IDXX’s Q1 EstimatesThe Zacks Consensus Estima ...

Company Overview - IDEXX Laboratories (IDXX) shares increased by 10% to close at $397.10, following a notable trading volume, contrasting with a 15.4% loss over the past four weeks [1] - The company is set to release its first-quarter financial results for 2025 on May 1, which has generated investor optimism [2] Financial Performance - In the last reported fourth quarter, IDEXX experienced year-over-year growth in both revenue and earnings, driven by the expansion of its global premium instrument installed base and net customer gains across testing modalities [2] - The upcoming quarterly earnings are expected to be $2.93 per share, reflecting a 4.3% increase year-over-year, with revenues projected at $1.02 billion, a 5.8% increase from the previous year [3] Earnings Estimates and Market Sentiment - The consensus EPS estimate for the upcoming quarter has been revised 1.4% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - IDEXX currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [4]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...